Intracerebral gadolinium deposition following blood-brain barrier disturbance in two different mouse models.
Mice
Animals
Contrast Media
/ pharmacology
Blood-Brain Barrier
/ diagnostic imaging
Gadolinium
/ pharmacology
Glioblastoma
Chromatography, Liquid
Prospective Studies
Retrospective Studies
Tandem Mass Spectrometry
Gadolinium DTPA
Magnetic Resonance Imaging
/ methods
Globus Pallidus
Disease Models, Animal
Organometallic Compounds
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 06 2023
22 06 2023
Historique:
received:
06
10
2022
accepted:
14
06
2023
medline:
26
6
2023
pubmed:
23
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
To evaluate the influence of the blood-brain barrier on neuronal gadolinium deposition in a mouse model after multiple intravenous applications of the linear contrast agent gadodiamide. The prospective study held 54 mice divided into three groups: healthy mice (A), mice with iatrogenic induced disturbance of the blood-brain barrier by glioblastoma (B) or cerebral infarction (C). In each group 9 animals received 10 iv-injections of gadodiamide (1.2 mmol/kg) every 48 h followed by plain T1-weighted brain MRI. A final MRI was performed 5 days after the last contrast injection. Remaining mice underwent MRI in the same time intervals without contrast application (control group). Signal intensities of thalamus, pallidum, pons, dentate nucleus, and globus pallidus-to-thalamus and dentate nucleus-to-pons ratios, were determined. Gadodiamide complex and total gadolinium amount were quantified after the last MR examination via LC-MS/MS and ICP-MS. Dentate nucleus-to-pons and globus pallidus-to-thalamus SI ratios showed no significant increase over time within all mice groups receiving gadodiamide, as well as compared to the control groups at last MR examination. Comparing healthy mice with group B and C after repetitive contrast administration, a significant SI increase could only be detected for glioblastoma mice in globus pallidus-to-thalamus ratio (p = 0.033), infarction mice showed no significant SI alteration. Tissue analysis revealed significantly higher gadolinium levels in glioblastoma group compared to healthy (p = 0.013) and infarction mice (p = 0.029). Multiple application of the linear contrast agent gadodiamide leads to cerebral gadolinium deposition without imaging correlate in MRI.
Identifiants
pubmed: 37349374
doi: 10.1038/s41598-023-36991-8
pii: 10.1038/s41598-023-36991-8
pmc: PMC10287697
doi:
Substances chimiques
gadodiamide
84F6U3J2R6
Contrast Media
0
Gadolinium
AU0V1LM3JT
Gadolinium DTPA
K2I13DR72L
Organometallic Compounds
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
10164Informations de copyright
© 2023. The Author(s).
Références
Radiology. 2014 Mar;270(3):834-41
pubmed: 24475844
Biometals. 2008 Aug;21(4):469-90
pubmed: 18344005
Radiology. 2017 Dec;285(3):839-849
pubmed: 28873047
Mol Imaging. 2008 Nov-Dec;7(6):248-62
pubmed: 19123995
Radiology. 2015 Jun;275(3):803-9
pubmed: 25633504
Radiology. 2015 Jul;276(1):228-32
pubmed: 25942417
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Apr 1;891-892:20-6
pubmed: 22391331
AJR Am J Roentgenol. 1999 Apr;172(4):1109-15
pubmed: 10587157
J Magn Reson Imaging. 2012 Nov;36(5):1060-71
pubmed: 23090917
J Am Soc Nephrol. 2006 Sep;17(9):2359-62
pubmed: 16885403
AJNR Am J Neuroradiol. 2008 Oct;29(9):1612-21
pubmed: 18583413
Invest Radiol. 2016 Nov;51(11):691-700
pubmed: 27175546
J Magn Reson Imaging. 2012 Feb;35(2):426-30
pubmed: 22127848
Metallomics. 2019 Feb 20;11(2):240-254
pubmed: 30516229
Neuroradiology. 2019 Feb;61(2):163-173
pubmed: 30377745
Nephrol Dial Transplant. 2006 Apr;21(4):1104-8
pubmed: 16431890
Metallomics. 2009 Nov;1(6):479-88
pubmed: 21305156
Invest Radiol. 2015 Dec;50(12):805-10
pubmed: 26523910
Invest Radiol. 2008 Dec;43(12):817-28
pubmed: 19002053
Radiology. 2018 Aug;288(2):424-433
pubmed: 29786486
Radiology. 2015 Jun;275(3):783-91
pubmed: 25848905
Invest Radiol. 1995 Jun;30(6):372-80
pubmed: 7490190
Biochim Biophys Acta. 2009 Apr;1788(4):842-57
pubmed: 19061857
Invest Radiol. 2017 Jul;52(7):396-404
pubmed: 28125438
Magn Reson Med Sci. 2018 Apr 10;17(2):111-119
pubmed: 29367513
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Br J Radiol. 2017 Nov;90(1079):20170115
pubmed: 28749164
Invest Radiol. 2014 Oct;49(10):685-90
pubmed: 24872007
Invest Radiol. 2021 Sep 1;56(9):535-544
pubmed: 33813574
Eur Radiol. 2006 Sep;16(9):2074-82
pubmed: 16625352
Invest Radiol. 2018 Sep;53(9):499-517
pubmed: 29659381
Radiology. 2015 Jun;275(3):630-4
pubmed: 25942418
Jpn J Radiol. 2016 Jan;34(1):3-9
pubmed: 26608061
Radiology. 2015 Jun;275(3):772-82
pubmed: 25742194
Invest Radiol. 2006 Mar;41(3):272-8
pubmed: 16481910
Invest Radiol. 2018 Sep;53(9):529-534
pubmed: 29652699
Eur Radiol. 2012 Nov;22(11):2371-81
pubmed: 22688125
Radiology. 2009 May;251(2):503-10
pubmed: 19401576
AJR Am J Roentgenol. 1984 Mar;142(3):619-24
pubmed: 6607655
Clin Cancer Res. 2019 May 1;25(9):2874-2886
pubmed: 30670496
Stroke. 2021 Aug;52(9):2939-2947
pubmed: 34266304
Epilepsia. 2012 Nov;53 Suppl 6:14-21
pubmed: 23134491
Radiology. 2011 Jan;258(1):222-8
pubmed: 21045180
Invest Radiol. 2016 Feb;51(2):83-9
pubmed: 26606548
Radiology. 2019 Feb;290(2):340-348
pubmed: 30422091
Neurotoxicology. 2007 Mar;28(2):257-62
pubmed: 16647136
AJNR Am J Neuroradiol. 2007 Sep;28(8):1474-9
pubmed: 17846194